This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
$119.00
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Falzetti F, Aversa F, Minelli O, Tabilio A . Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.
Becker PS, Wagle M, Matous S . Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45–49.
O'Malley DP, Whalen M, Banks PM . Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. Am J Hematol 2003; 73: 294–295.
Zimmer BM, Berdel WE, Ludwig WD, Notter M, Rheufi B, Thiel E . Fatal spleen rupture during induction chemotherapy with GM-CSF priming for acute monocytic leukemia. Leuk Res 1993; 17: 277–283.
Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V . Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 2003; 74: 131–135.
Arshad M, Seiter K, Bilaniuk J, Qureshi A, Patil A, Ramaswamy G et al. Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005; 23: 8533–8534.
Stroncek D, Shawker T, Follmann D, Leitman SF . G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43: 609–613.
Picardi M, De Rosa G, Selleri C, Scarpato N, Soscia E, Martinelli V et al. Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. Haematologica 2003; 88: 794–800.
Fukushima N, Nishina H, Koishihara Y, Ohkawa H . Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor. Blood 1992; 80: 1914–1922.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuendgen, A., Fenk, R., Bruns, I. et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 38, 69–70 (2006). https://doi.org/10.1038/sj.bmt.1705382
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705382
Further reading
-
Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis
Bone Marrow Transplantation (2015)
-
Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells
Bone Marrow Transplantation (2013)
-
SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization
Bone Marrow Transplantation (2011)
-
Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT
Bone Marrow Transplantation (2009)
-
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator
Leukemia (2009)